Royalty Pharma plc Class A (RPRX)

NASDAQ · Manufacturing · Pharmaceutical preparations

$58.22−$0.0500 (−0.09%)As of the Sep 28, 2026 close; data may be delayed.

RPRX price, last 12 months

Sep 16, 2025Sep 28, 2026

Daily closes over the last 260 trading sessions: +64.4%. Highest close $63.96 on Sep 4, 2026, lowest $34.90 on Sep 25, 2025. Market data may be delayed.

Key stats

Previous close: $58.27
Open: $57.89
Day range: $57.63 – $58.40
52-week range: $34.63 – $64.38
Volume: 67.9K
Avg volume (20 days): 3.2M
Market cap: $25.9B

Performance

1W−0.4%

1M−6.0%

3M+2.0%

6M+25.6%

YTD+50.7%

1Y+66.8%

vs S&P 500, 1Y+50.1 pts

Technicals and fundamentals

About Royalty Pharma plc Class A

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Sector: Manufacturing
Industry: Pharmaceutical preparations
Listed on: NASDAQ
Market cap: $25.9B

royaltypharma.com

Technicals and fundamentals

Technicals

RSI (14)42.6mid-range

vs 50-day average−2.1%

vs 200-day average+14.9%price between averages

MACDBelow signal

Daily range (ATR)2.3%average true range, % of price

52w low $34.6352w high $64.38

Where price sits today against its own history. A description, not a forecast.

Valuation

P/E (trailing)19.20.79x Manufacturing median (24.4)

P/E (forward)10.2

PEG1.36

Price / sales10.23

Price / book3.75

EV / EBITDA23.1

P/E since Jun 117.5 – 21.1

Company figures as of Sep 25, 2026.

Analysts

Consensus—— on 1 (strong buy) to 5 (strong sell)

Analysts8

Average target$65.12+11.9% from today

Price targets are opinions and tend to lean optimistic.

Earnings

Quarter ended	EPS	YoY	Revenue	YoY
Jun '26	0.04	−43%	$674.1M	+17%
Mar '26	0.67	+22%	$630.6M	+11%
Dec '25	0.50	—	$622M	—
Sep '25	0.67	−45%	$609.3M	+8%
Jun '25	0.07	−70%	$578.7M	+8%
Mar '25	0.55	+5,400%	$568.2M	0%
Sep '24	1.21	+656%	$564.7M	+5%
Jun '24	0.23	−54%	$537.3M	0%

By the quarter each report covers, against the same quarter a year earlier. Growth from a loss is left blank: a percentage there reads backwards.

Dividends & splits

Paid, last 12 months$0.93quarterly

Yield at today's price1.59%

Change vs the year before+6.3%

Payout ratio49%share of earnings paid out

Aug 14 $0.24May 15 $0.24Feb 20 $0.24Nov 14 $0.22Aug 15 $0.22May 16 $0.22

Splits

Oct 15, 20101-for-4 (reverse)

Seasonality

+6.5

+2.8

-0.8

+1.6

+0.0

+0.5

+3.7

-0.6

-4.3

+3.1

+2.1

-2.8

Average return in each calendar month, Oct 31, 2021 to Aug 31, 2026. 5 years is 5 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.

	Q3 FY2024Sep 30, 2024	Q4 FY2024Dec 31, 2024	Q1 FY2025Mar 31, 2025	Q2 FY2025Jun 30, 2025	Q3 FY2025Sep 30, 2025	Q4 FY2025Dec 31, 2025	Q1 FY2026Mar 31, 2026	Q2 FY2026Jun 30, 2026
Income
Revenue	$564.7M	$593.6M	$568.2M	$578.7M	$609.3M	$622.0M	$630.6M	$674.1M
vs a year before	+5%	0%	0%	+8%	+8%	+5%	+11%	+17%
Operating income	$735.1M	$361.5M	$534.2M	$209.8M	$427.2M	$388.4M	$563.0M	$133.1M
Operating margin	130.2%	60.9%	94.0%	36.3%	70.1%	62.4%	89.3%	19.8%
Net income	$544.0M	$208.2M	$239.3M	$32.2M	$288.2M	$214.2M	$294.7M	$17.9M
Net margin	96.3%	35.1%	42.1%	5.6%	47.3%	34.4%	46.7%	2.7%
EPS, diluted	1.21	0.47	0.55	0.07	0.67	0.50	0.67	0.04
vs a year before	+656%	−57%	+5,400%	−70%	−45%	+6%	+22%	−43%
Cash flow
From operations	$703.6M	$742.5M	$596.1M	$364.0M	$702.6M	$827.1M	$718.2M	$728.5M
At period end
Cash	$950.1M	$929.0M	$1.1B	$631.9M	$938.9M	$618.7M	$586.4M	$812.0M
Debt	$7.6B	$7.6B	$7.6B	$8.0B	$8.9B	$9.0B	$9.0B	$9.0B
Shareholders' equity	$10.3B	$10.3B	$9.8B	$9.5B	$9.6B	$9.7B	$9.9B	$9.8B

Q3 FY2024Sep 30, 2024

Q4 FY2024Dec 31, 2024

Q1 FY2025Mar 31, 2025

Q2 FY2025Jun 30, 2025

Q3 FY2025Sep 30, 2025

Q4 FY2025Dec 31, 2025

Q1 FY2026Mar 31, 2026

Q2 FY2026Jun 30, 2026

Income

Revenue

$564.7M

$593.6M

$568.2M

$578.7M

$609.3M

$622.0M

$630.6M

$674.1M

vs a year before

+5%

+8%

+5%

+11%

+17%

Operating income

$735.1M

$361.5M

$534.2M

$209.8M

$427.2M

$388.4M

$563.0M

$133.1M

Operating margin

130.2%

60.9%

94.0%

36.3%

70.1%

62.4%

89.3%

19.8%

Net income

$544.0M

$208.2M

$239.3M

$32.2M

$288.2M

$214.2M

$294.7M

$17.9M

Net margin

96.3%

35.1%

42.1%

5.6%

47.3%

34.4%

46.7%

2.7%

EPS, diluted

1.21

0.47

0.55

0.07

0.67

0.50

0.67

0.04

vs a year before

+656%

−57%

+5,400%

−70%

−45%

+6%

+22%

−43%

Cash flow

From operations

$703.6M

$742.5M

$596.1M

$364.0M

$702.6M

$827.1M

$718.2M

$728.5M

At period end

Cash

$950.1M

$929.0M

$1.1B

$631.9M

$938.9M

$618.7M

$586.4M

$812.0M

Debt

$7.6B

$8.0B

$8.9B

$9.0B

Shareholders' equity

$10.3B

$9.8B

$9.5B

$9.6B

$9.7B

$9.9B

$9.8B

Royalty Pharma plc Class A (RPRX)

RPRX price, last 12 months

Key stats

Performance

Technicals and fundamentals

About Royalty Pharma plc Class A

Royalty Pharma plc Class A (RPRX)

RPRX price, last 12 months

Key stats

Performance

Technicals and fundamentals

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

About Royalty Pharma plc Class A

News

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

News

RPRX price, last 12 months

Key stats

Performance

Technicals and fundamentals

About Royalty Pharma plc Class A

Recent news about RPRX

Chart RPRX with indicators, scan for setups and get alerts

RPRX price, last 12 months

Key stats

Performance

Technicals and fundamentals

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

About Royalty Pharma plc Class A

Recent news about RPRX

News

Chart RPRX with indicators, scan for setups and get alerts

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

News